[{"id":"54e610ca-41de-4129-a9cc-28b0a7d31044","acronym":"SPARC-1","url":"https://clinicaltrials.gov/study/NCT04028245","created_at":"2021-01-29T07:19:33.502Z","updated_at":"2025-02-25T15:43:37.351Z","phase":"Phase 1","brief_title":"A Study of Combination Spartalizumab and Canakinumab in Patients With Localized Clear Cell Renal Cell Carcinoma","source_id_and_acronym":"NCT04028245 - SPARC-1","lead_sponsor":"Columbia University","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e spartalizumab (PDR001) • Ilaris (canakinumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 08/15/2019","start_date":" 08/15/2019","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-07-09"},{"id":"7a2918a3-5cca-4af4-9ede-643ba7496c81","acronym":"","url":"https://clinicaltrials.gov/study/NCT01745588","created_at":"2021-01-18T07:39:01.782Z","updated_at":"2025-02-25T14:33:53.694Z","phase":"Phase 2","brief_title":"Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma","source_id_and_acronym":"NCT01745588","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" CD34","pipe":"","alterations":" ","tags":["CD34"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e dexamethasone • pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 23","initiation":"Initiation: 12/01/2012","start_date":" 12/01/2012","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-07-03"},{"id":"80ae9b9a-9383-4fbe-a030-18f6cfe6115b","acronym":"","url":"https://clinicaltrials.gov/study/NCT03798626","created_at":"2021-01-18T18:47:09.510Z","updated_at":"2024-07-02T16:35:03.688Z","phase":"Phase 1","brief_title":"Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers","source_id_and_acronym":"NCT03798626","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • paclitaxel • 5-fluorouracil • Cabometyx (cabozantinib tablet) • Cyramza (ramucirumab) • oxaliplatin • irinotecan • leucovorin calcium • gevokizumab (VPM087)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 167","initiation":"Initiation: 05/22/2019","start_date":" 05/22/2019","primary_txt":" Primary completion: 03/01/2023","primary_completion_date":" 03/01/2023","study_txt":" Completion: 12/30/2024","study_completion_date":" 12/30/2024","last_update_posted":"2024-05-14"},{"id":"8deded4a-9926-4f1a-a26a-90e378ae94dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04577755","created_at":"2023-11-14T19:14:53.297Z","updated_at":"2024-07-02T16:35:08.364Z","phase":"Phase 2","brief_title":"Pomalidomide Treatment in Patients With Kaposi Sarcoma","source_id_and_acronym":"NCT04577755","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Recruiting","enrollment":" Enrollment 45","initiation":"Initiation: 03/18/2022","start_date":" 03/18/2022","primary_txt":" Primary completion: 03/01/2026","primary_completion_date":" 03/01/2026","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2024-04-22"},{"id":"dac8c5cc-c11e-498d-83e0-ff37aaef885f","acronym":"CANOPY-1","url":"https://clinicaltrials.gov/study/NCT03631199","created_at":"2021-01-18T17:50:06.187Z","updated_at":"2024-07-02T16:35:13.813Z","phase":"Phase 3","brief_title":"Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects","source_id_and_acronym":"NCT03631199 - CANOPY-1","lead_sponsor":"Novartis Pharmaceuticals","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • pemetrexed • Ilaris (canakinumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 673","initiation":"Initiation: 12/21/2018","start_date":" 12/21/2018","primary_txt":" Primary completion: 08/09/2021","primary_completion_date":" 08/09/2021","study_txt":" Completion: 06/07/2027","study_completion_date":" 06/07/2027","last_update_posted":"2024-03-20"},{"id":"c4ec5c4c-4c79-4761-96b6-d089338bc996","acronym":"","url":"https://clinicaltrials.gov/study/NCT06038526","created_at":"2023-09-14T14:13:05.141Z","updated_at":"2024-07-02T16:35:36.912Z","phase":"Phase 2","brief_title":"Evaluation of Canakinumab in High-Risk Former-Smokers","source_id_and_acronym":"NCT06038526","lead_sponsor":"Peter Shields","biomarkers":" IL1B • CASP1","pipe":"","alterations":" ","tags":["IL1B • CASP1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ilaris (canakinumab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 09/30/2023","start_date":" 09/30/2023","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-09-14"},{"id":"5766f363-23d7-4ddf-aa99-822a48d173b1","acronym":"","url":"https://clinicaltrials.gov/study/NCT02185820","created_at":"2021-02-04T20:52:56.667Z","updated_at":"2024-07-02T16:35:44.252Z","phase":"Phase 1/2","brief_title":"Phase I/II Study of Carfilzomib, Pomalidomide and Dexamethasone in Relapsed And/Or Refractory Multiple Myeloma Patients (CPD)","source_id_and_acronym":"NCT02185820","lead_sponsor":"European Myeloma Network","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carfilzomib • dexamethasone • pomalidomide"],"overall_status":"Completed","enrollment":" Enrollment 57","initiation":"Initiation: 06/01/2014","start_date":" 06/01/2014","primary_txt":" Primary completion: 07/01/2015","primary_completion_date":" 07/01/2015","study_txt":" Completion: 01/01/2023","study_completion_date":" 01/01/2023","last_update_posted":"2023-06-30"},{"id":"5549ff6d-d0c0-4524-812c-e784acd2dec2","acronym":"","url":"https://clinicaltrials.gov/study/NCT04305444","created_at":"2021-01-18T20:52:47.509Z","updated_at":"2024-07-02T16:35:49.171Z","phase":"Phase 2","brief_title":"Study of a Triple Combination Therapy, DTRM-555, in Patients With R/R CLL or R/R Non-Hodgkin's Lymphomas","source_id_and_acronym":"NCT04305444","lead_sponsor":"Zhejiang DTRM Biopharma","biomarkers":" BCL2","pipe":"","alterations":" ","tags":["BCL2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide • DTRM-555 • DTRMWXHS-12"],"overall_status":"Recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 04/24/2020","start_date":" 04/24/2020","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 03/01/2024","study_completion_date":" 03/01/2024","last_update_posted":"2023-05-02"},{"id":"609b62e0-5459-4e6f-b8b3-1e6b3e397774","acronym":"","url":"https://clinicaltrials.gov/study/NCT01495598","created_at":"2022-11-05T15:11:43.110Z","updated_at":"2024-07-02T16:36:01.485Z","phase":"Phase 1/2","brief_title":"Pomalidomide for Kaposi Sarcoma in People With or Without HIV","source_id_and_acronym":"NCT01495598","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD8 • CD4","pipe":"","alterations":" ","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Completed","enrollment":" Enrollment 28","initiation":"Initiation: 01/10/2012","start_date":" 01/10/2012","primary_txt":" Primary completion: 05/17/2022","primary_completion_date":" 05/17/2022","study_txt":" Completion: 05/17/2022","study_completion_date":" 05/17/2022","last_update_posted":"2022-11-01"},{"id":"67c8cf1c-10de-492c-b487-6be1c0e1cff9","acronym":"","url":"https://clinicaltrials.gov/study/NCT05395260","created_at":"2022-05-27T11:56:25.157Z","updated_at":"2024-07-02T16:36:05.163Z","phase":"Phase 1","brief_title":"FL- 101 Study in Non-Metastatic MIBC","source_id_and_acronym":"NCT05395260","lead_sponsor":"Flame Biosciences","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e FL-101"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/22/2022","start_date":" 08/22/2022","primary_txt":" Primary completion: 11/28/2022","primary_completion_date":" 11/28/2022","study_txt":" Completion: 12/28/2022","study_completion_date":" 12/28/2022","last_update_posted":"2022-08-19"},{"id":"2fb657ac-eed2-45a0-bd11-acbeb884bff1","acronym":"SPACE","url":"https://clinicaltrials.gov/study/NCT03113942","created_at":"2021-01-29T07:14:31.583Z","updated_at":"2024-07-02T16:36:14.293Z","phase":"Phase 2","brief_title":"Study of Pomalidomide in Anal Cancer Precursors","source_id_and_acronym":"NCT03113942 - SPACE","lead_sponsor":"Kirby Institute","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e pomalidomide"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 26","initiation":"Initiation: 06/14/2017","start_date":" 06/14/2017","primary_txt":" Primary completion: 03/31/2019","primary_completion_date":" 03/31/2019","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-03-31"},{"id":"3aae4a72-17aa-4ae7-b12d-0acae1fabb95","acronym":"","url":"https://clinicaltrials.gov/study/NCT04758949","created_at":"2021-02-17T14:01:03.886Z","updated_at":"2024-07-02T16:36:18.676Z","phase":"Phase 2","brief_title":"FL-101 in Surgically Resectable Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT04758949","lead_sponsor":"Flame Biosciences","biomarkers":" CRP","pipe":"","alterations":" ","tags":["CRP"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • FL-101"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 08/25/2021","start_date":" 08/25/2021","primary_txt":" Primary completion: 12/22/2021","primary_completion_date":" 12/22/2021","study_txt":" Completion: 12/22/2021","study_completion_date":" 12/22/2021","last_update_posted":"2022-01-11"}]